Zacks: Analysts Expect Antares Pharma Inc (ATRS) to Announce -$0.04 EPS

Share on StockTwits

Equities research analysts expect Antares Pharma Inc (NASDAQ:ATRS) to announce earnings per share (EPS) of ($0.04) for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Antares Pharma’s earnings. The lowest EPS estimate is ($0.04) and the highest is ($0.03). Antares Pharma reported earnings of ($0.03) per share during the same quarter last year, which indicates a negative year over year growth rate of 33.3%. The business is scheduled to issue its next earnings report on Tuesday, August 6th.

According to Zacks, analysts expect that Antares Pharma will report full-year earnings of ($0.10) per share for the current fiscal year, with EPS estimates ranging from ($0.13) to ($0.06). For the next year, analysts expect that the company will post earnings of $0.24 per share, with EPS estimates ranging from $0.00 to $0.60. Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Antares Pharma.

Antares Pharma (NASDAQ:ATRS) last issued its quarterly earnings data on Thursday, May 2nd. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.01. Antares Pharma had a negative return on equity of 17.94% and a negative net margin of 7.91%. The firm had revenue of $23.29 million during the quarter, compared to analyst estimates of $17.46 million.

ATRS has been the subject of a number of recent analyst reports. HC Wainwright restated a “buy” rating and set a $4.50 price objective on shares of Antares Pharma in a research note on Monday, May 6th. BidaskClub upgraded Antares Pharma from a “hold” rating to a “buy” rating in a research note on Wednesday, March 6th. TheStreet upgraded Antares Pharma from a “d” rating to a “c” rating in a research note on Friday, March 1st. Cowen initiated coverage on Antares Pharma in a research note on Monday, February 25th. They set an “outperform” rating and a $1.99 price objective for the company. Finally, Raymond James raised their price objective on Antares Pharma from $5.25 to $5.65 and gave the company a “strong-buy” rating in a research note on Monday, March 4th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Antares Pharma currently has an average rating of “Buy” and a consensus price target of $4.83.

NASDAQ ATRS traded up $0.01 during mid-day trading on Thursday, reaching $2.83. 27,506 shares of the company’s stock traded hands, compared to its average volume of 916,586. Antares Pharma has a 1-year low of $2.40 and a 1-year high of $3.96. The company has a quick ratio of 1.90, a current ratio of 2.28 and a debt-to-equity ratio of 0.50. The firm has a market cap of $453.71 million, a PE ratio of -70.38 and a beta of 1.03.

In other news, Director Thomas J. Garrity sold 30,000 shares of Antares Pharma stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $2.67, for a total value of $80,100.00. Following the completion of the transaction, the director now owns 190,213 shares in the company, valued at approximately $507,868.71. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Jacques Gonella sold 200,000 shares of Antares Pharma stock in a transaction that occurred on Tuesday, February 26th. The stock was sold at an average price of $3.65, for a total value of $730,000.00. Following the completion of the transaction, the director now owns 9,385,848 shares of the company’s stock, valued at approximately $34,258,345.20. The disclosure for this sale can be found here. In the last quarter, insiders sold 322,078 shares of company stock valued at $1,086,334. Insiders own 5.49% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. raised its stake in Antares Pharma by 3.1% during the 4th quarter. BlackRock Inc. now owns 10,234,202 shares of the specialty pharmaceutical company’s stock valued at $27,839,000 after acquiring an additional 304,945 shares in the last quarter. Vanguard Group Inc raised its stake in Antares Pharma by 1.3% during the 3rd quarter. Vanguard Group Inc now owns 6,487,465 shares of the specialty pharmaceutical company’s stock valued at $21,798,000 after acquiring an additional 84,181 shares in the last quarter. Vanguard Group Inc. raised its stake in Antares Pharma by 1.3% during the 3rd quarter. Vanguard Group Inc. now owns 6,487,465 shares of the specialty pharmaceutical company’s stock valued at $21,798,000 after acquiring an additional 84,181 shares in the last quarter. Sargent Investment Group LLC bought a new stake in Antares Pharma during the 4th quarter valued at $8,422,000. Finally, Morgan Stanley raised its stake in Antares Pharma by 160.9% during the 1st quarter. Morgan Stanley now owns 2,130,832 shares of the specialty pharmaceutical company’s stock valued at $6,457,000 after acquiring an additional 1,314,002 shares in the last quarter. 40.48% of the stock is currently owned by hedge funds and other institutional investors.

About Antares Pharma

Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Recommended Story: Outstanding Shares, Buying and Selling Stocks

Get a free copy of the Zacks research report on Antares Pharma (ATRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Schwab US Large-Cap ETF  Shares Sold by Elmwood Wealth Management Inc.
Schwab US Large-Cap ETF Shares Sold by Elmwood Wealth Management Inc.
Elmwood Wealth Management Inc. Reduces Position in Invesco S&P 500 Equal Weight ETF
Elmwood Wealth Management Inc. Reduces Position in Invesco S&P 500 Equal Weight ETF
Mastercard Inc  Shares Bought by Rehmann Capital Advisory Group
Mastercard Inc Shares Bought by Rehmann Capital Advisory Group
3M Co  Shares Sold by Diversified Trust Co
3M Co Shares Sold by Diversified Trust Co
Diversified Trust Co Acquires 3,375 Shares of Mastercard Inc
Diversified Trust Co Acquires 3,375 Shares of Mastercard Inc
Financial Insights Inc. Purchases 619 Shares of SPDR MSCI USA StrategicFactors ETF
Financial Insights Inc. Purchases 619 Shares of SPDR MSCI USA StrategicFactors ETF


 
© 2006-2019 Zolmax.